The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely terrible.

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Obesity alters how medications work, increasing the risk of underdosing, overdosing, and unknown interactions. Are package ...

The discontinuation of danuglipron, a potential obesity drug, highlights Pfizer's struggle to develop successful new drugs, impacting its market position. Pfizer faces significant challenges ...

Multiple randomised controlled trials have demonstrated that treatment with glucagon-like ... out and uptake of novel medications for obesity. A new wave of digital health providers are emerging ...

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

The study, conducted by researchers in Finland, found that children who took antibiotics before the age of two were 20 per ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...